secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001746473-25-000173
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics Q3 net loss narrows to $26.3M; BEACON-IPF close out near completion
--------------------------------------------------------------------------------

- Net loss $26.3M vs $57.8M YoY; R&D expense fell to $17.9M from $47.8M.
- Cash, equivalents and short-term investments $243.3M as of Sept 30, 2025.
- Phase 1 trial of PLN-101095 completed enrollment; data expected Q4 2025.
- BEACON-IPF close out activities to be completed in Q4 2025.
- Voluntary prepayment of Oxford Finance LLC loan completed in October 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/0001746473-25-000173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000173/plrx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001746473-25-000173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer